By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



20451 Seneca Meadows Parkway

Germantown  Maryland  20876-7005  U.S.A.
Phone: 301-515-7260 Fax: 301-515-0988


We are a medical technology company focused on the design, development and commercialization of glucose monitoring systems to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Our first generation continuous glucose monitoring, or CGM, system is a reliable, long-term, implantable CGM system that we have designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 days, as compared to five to seven days for currently available CGM systems.




CEO: Timothy T. Goodnow, PhD

CFO: R. Don Elsey

Chief Medical Officer: E. Lynne Kelley, M.D., FACS

Key Statistics

Ownership: Private

Web Site: Senseonics


Company News
Senseonics Prices $25 Million Public Offering of Common Stock 8/18/2017 7:09:44 AM
Senseonics Leads Development Efforts Of A Long-Term “Artificial Pancreas” System For Use In The International Diabetes Closed Loop Trial 7/25/2017 8:21:39 AM
Senseonics And TypeZero Sign Development Agreement For Artificial Pancreas And Decision Support Systems 5/12/2017 9:54:34 AM
Senseonics Reports First Quarter 2017 Financial Results 5/5/2017 9:04:58 AM
Senseonics Appoints Michael J. Gill, Vice President Of Sales 4/20/2017 6:56:49 AM
Senseonics Schedules First Quarter 2017 Earnings Release And Conference Call For May 4, 2017 At 4:30 P.M. Eastern Time 4/19/2017 11:02:34 AM
Senseonics Draws Third Tranche Of Existing Loan Facility 3/31/2017 9:15:46 AM
Senseonics Reports Fourth Quarter 2016 Financial Results 2/24/2017 6:22:45 AM
Senseonics Schedules Fourth Quarter And Full Year 2016 Earnings Release And Conference Call For February 23, 2017 At 4:30 P.M. Eastern Time 2/14/2017 12:54:38 PM
Senseonics Expands Distribution Agreement With Roche (RHHBY) 12/2/2016 8:13:18 AM